A multifunctional nanoparticle as a prophylactic and therapeutic approach targeting respiratory syncytial virus

Markoutsa, Eleni; McGill, Andrew R.; Singer, Anthony; Jadhav, Heta; Mohapatra, Subhra; Mohapatra, Shyam S.

doi:10.1016/j.nano.2020.102325

Cited by 5 publications

(7 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Combining anti-fusion, anti-immune subversion, and anti-replication approaches by utilizing an NP system of phospholipid-coated chitosan NPs, will hopefully elicit a powerful immune purpose [92]. The mRNA-based vaccine that uses LNP for the delivery system improves the immune response to the vaccine, most likely through protecting the mRNA from enzymes and enabling efficient uptake and intracellular release of the mRNA in target cells [93].…”

Section: Lnps As a Delivery Systemmentioning

confidence: 99%

Lipid Nanoparticles as Promising Carriers for mRNA Vaccines for Viral Lung Infections

et al. 2023

View full text Add to dashboard Cite

In recent years, there has been an increase in deaths due to infectious diseases, most notably in the context of viral respiratory pathogens. Consequently, the focus has shifted in the search for new therapies, with attention being drawn to the use of nanoparticles in mRNA vaccines for targeted delivery to improve the efficacy of these vaccines. Notably, mRNA vaccine technologies denote as a new era in vaccination due to their rapid, potentially inexpensive, and scalable development. Although they do not pose a risk of integration into the genome and are not produced from infectious elements, they do pose challenges, including exposing naked mRNAs to extracellular endonucleases. Therefore, with the development of nanotechnology, we can further improve their efficacy. Nanoparticles, with their nanometer dimensions, move more freely in the body and, due to their small size, have unique physical and chemical properties. The best candidates for vaccine mRNA transfer are lipid nanoparticles (LNPs), which are stable and biocompatible and contain four components: cationic lipids, ionizable lipids, polyethylene glycols (PEGs), and cholesterol, which are used to facilitate cytoplasmic mRNA delivery. In this article, the components and delivery system of mRNA-LNP vaccines against viral lung infections such as influenza, coronavirus, and respiratory syncytial virus are reviewed. Moreover, we provide a succinct overview of current challenges and potential future directions in the field.

show abstract

Section: Lnps As a Delivery Systemmentioning

confidence: 99%

Lipid Nanoparticles as Promising Carriers for mRNA Vaccines for Viral Lung Infections

et al. 2023

View full text Add to dashboard Cite

show abstract

“…RSV replicates inside the infected cells and prevents further viral spread and disease development. The balance and durability of the plasmid DNA are confirmed by the liposomal layer present between the core and the shell [ 63 ]. Similarly, curcumin-encapsulated CNPs exhibited to have an antiviral effect against Hepatitis C Virus which was confirmed in Human Hepatoma Cell Lines [ 64 ].…”

Section: Wide Spectrum Application Of Cnpsmentioning

confidence: 99%

A clinical perspective of chitosan nanoparticles for infectious disease management

2023

View full text Add to dashboard Cite

“…The existence of injury in pulmonary parenchyma and pleura was evaluated in each biological sample. These values were added, and the determined level of pulmonary damage was determined as minimum (1-6), average (7-10), moderate (10)(11)(12)(13)(14), or severe (>14).…”

Section: In Vivo Assays Statementmentioning

confidence: 99%

“…Metallic nanoparticles show antiviral activity against respiratory viruses [ 9 ]. Another study made with nanoparticles against RSV was shown to have very promising data as prophylactic or therapeutic approaches, placing nanoparticles as a very interesting and effective tool; meanwhile, the vaccine is developed [ 10 ]. Additionally, mice models had improved the present airway epithelial cells culture as well as the data obtained and mimic real respiratory infections [ 5 , 11 , 12 ].…”

Section: Introductionmentioning

confidence: 99%

Role of G2-S16 Polyanionic Carbosilane Dendrimer in the Prevention of Respiratory Syncytial Virus Infection In Vitro and In Vivo in Mice

et al. 2021

View full text Add to dashboard Cite

The respiratory syncytial virus (RSV) causes respiratory infection and bronchiolitis, requiring hospitalization mainly in infants. The interaction between RSV, envelope glycoproteins G and F, and cell surface heparan sulfate proteoglycans (HSPG) is required for binding and entry into the host cells. A G2-S16 polyanionic carbosilane dendrimer was identified as a possible RSV inhibitor. We speculated that the G2-S16 dendrimer adheres to the host cell-surface HSPG, acts through binding to HS receptors, and prevents further RSV infection. The G2-S16 dendrimer was non-toxic when applied intranasally to Balb/c mice, and interestingly enough, this G2-S16 dendrimer inhibits 85% RSV. Therefore, our G2-S16 dendrimer could be a candidate for developing a new possible therapy against RSV infection.

show abstract

A multifunctional nanoparticle as a prophylactic and therapeutic approach targeting respiratory syncytial virus

Cited by 5 publications

References 59 publications

Lipid Nanoparticles as Promising Carriers for mRNA Vaccines for Viral Lung Infections

Lipid Nanoparticles as Promising Carriers for mRNA Vaccines for Viral Lung Infections

A clinical perspective of chitosan nanoparticles for infectious disease management

Role of G2-S16 Polyanionic Carbosilane Dendrimer in the Prevention of Respiratory Syncytial Virus Infection In Vitro and In Vivo in Mice

Contact Info

Product

Resources

About